BOSTON, Feb. 28, 2025 /PRNewswire/ -- Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design, today announced a collaboration and ...

For a drug to work, the molecule must bind to its target. That’s tricky for elusive targets lacking typical binding sites, but that hurdle can be overcome with molecular glue, a molecule that brings ...

Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise ...

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop and commercialize molecular glue ...